What Is Interleukin Studied For? Research Areas, Per the Literature

Interleukin is not a single molecule. The word names a large family of signalling proteins, or cytokines, that immune cells use to communicate with each other and with tissue. Numbered members such as interleukin 1 beta, interleukin 2, interleukin 5, interleukin 6, interleukin 12, interleukin 17 and interleukin 33 have distinct biology, distinct receptors and distinct research histories. For that reason, the question of what interleukin has been studied for only has meaningful answers once a specific interleukin and a specific disease setting are named.

Interleukin names a family of signalling proteins rather than one medicine, so no single FDA status covers it; specific products such as aldesleukin (Proleukin, an interleukin-2) hold their own FDA approvals. This page is not guidance. Separately, it is a regulatory fact that several engineered biologic drugs which either supply or block a named interleukin pathway are prescription products reviewed under their own brand names and their own labels; those products are not interchangeable with the general term interleukin, and nothing on this page describes how any of them is administered.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question. Background on the cytokine family is collected on the interleukin learn hub.

Two Opposite Research Strategies

Published work splits along a simple line. One line of research administers an interleukin to amplify an immune response, which is the approach taken with interleukin 2 and interleukin 12 in oncology, as described in a 2024 review of interleukin 2 therapy in cancer and autoimmune disease (PMID 38421721). The other line blocks an interleukin or its receptor to quiet inflammation, which is the approach behind interleukin 1 beta targeted strategies examined in a 2019 review of atherosclerotic cardiovascular disease (PMID 31078457). Understanding which direction a study took matters more than the interleukin number itself.

Oncology: Interleukin 2 and Interleukin 12

Interleukin 2

Interleukin 2 has one of the longest clinical research records in the family. A 2024 narrative review in the Journal of Interferon and Cytokine Research summarised human experience with high dose interleukin 2 in cancer alongside low dose strategies explored in autoimmune disease, and described the dose dependent split between effector cell stimulation and regulatory T cell expansion (PMID 38421721). That review is the main reference point on this page for interleukin 2, and it reported that toxicity has historically constrained the high dose approach in human oncology (PMID 38421721).

Interleukin 12

Interleukin 12 has been studied as a tumour directed immune stimulant, and a 2020 commentary in Clinical Cancer Research discussed delivery strategies intended to concentrate interleukin 12 activity in the tumour rather than systemically, a problem driven by the systemic toxicity seen in earlier human work (PMID 33004432). The framing in that piece was translational, meaning it described engineering and delivery concepts rather than reporting a new randomised human outcome (PMID 33004432).

Interleukins as Markers in Liver Cancer

A 2020 systematic review in Clinica Chimica Acta catalogued the roles of multiple interleukins in hepatocellular carcinoma, covering both tumour promoting and tumour suppressing signalling and the use of circulating interleukin levels as candidate biomarkers (PMID 32142718). Researchers in that review handled interleukins mainly as disease biology and measurement targets rather than as administered agents (PMID 32142718).

Psoriatic Disease: Interleukin 17 Blockade

Interleukin 17 is one of the most actively developed blocking targets in dermatology. A 2025 pipeline review in the American Journal of Clinical Dermatology examined next generation anti interleukin 17 agents for psoriatic disease, describing how newer molecules differ from earlier ones in which interleukin 17 family members they neutralise (PMID 39982633). Because it is a pipeline review, much of the material concerned agents still moving through human development rather than settled long term outcome data (PMID 39982633).

Nail involvement has been treated as a separate research question. A 2019 updated review in Acta Dermato Venereologica appraised available treatments for nail psoriasis including biologics that target interleukin pathways, and noted that nail disease responds on a different timescale than skin disease (PMID 30521057). The review combined published evidence with expert opinion, which is a weaker evidence grade than a pooled randomised analysis (PMID 30521057).

Eosinophilic Airway and Vasculitic Disease: Interleukin 5

Interleukin 5 drives eosinophil maturation and survival, which made it a target in eosinophil driven disease. A 2025 comparative review in Biomolecules examined interleukin 5 targeting with mepolizumab and benralizumab in eosinophilic granulomatosis with polyangiitis, contrasting an agent that neutralises the cytokine with one that targets the receptor on eosinophils (PMID 40305320). The authors framed the comparison around treatment strategy in that specific vasculitis population rather than general asthma care (PMID 40305320).

Childhood Asthma: Interleukin 33 as a Measured Marker

A 2017 systematic review and meta analysis in Allergologia et Immunopathologia pooled human studies of interleukin 33 in children with asthma and reported higher circulating interleukin 33 levels in asthmatic children compared with controls (PMID 28410870). That is an association in measured biomarker levels, not evidence that giving or blocking interleukin 33 changes asthma outcomes in children, and the review did not establish causation (PMID 28410870).

Cardiovascular Disease: Interleukin 1 Beta

The inflammatory hypothesis of atherosclerosis put interleukin 1 beta at the centre of cardiovascular immunology research. A 2019 review in Revista Espanola de Cardiologia assessed the potential therapeutic value of interleukin 1 beta targeted strategies in atherosclerotic cardiovascular disease, setting out the rationale and the clinical questions that remained open (PMID 31078457). A 2019 review in the European Heart Journal placed interleukin directed approaches inside the wider field of immunotherapy for cardiovascular disease, including the trade off between dampening inflammation and preserving host defence (PMID 31121017).

Sepsis Subgroups: Interleukin 1 Receptor Blockade

A 2016 reanalysis published in Critical Care Medicine revisited a prior phase III trial of interleukin 1 receptor blockade in sepsis and reported that patients with features of macrophage activation syndrome, defined by concurrent hepatobiliary dysfunction and disseminated intravascular coagulation, showed reduced mortality, whereas the original overall trial population had not shown benefit (PMID 26584195). Researchers presented this as a hypothesis generating subgroup result requiring prospective confirmation rather than a settled conclusion (PMID 26584195).

Immune Tolerance: Interleukin 2 and Regulatory T Cells

A 2013 review in JAK STAT described how interleukin 2 signalling through STAT5 supports the development and function of regulatory T cells, the cell population that restrains autoimmunity (PMID 24058794). This is mechanistic literature drawn largely from cellular and animal immunology, and it explains why the same cytokine has been investigated both to activate immunity in cancer and to restrain it in autoimmune disease (PMID 38421721).

Castleman Disease: Interleukin 6 Blockade

A 2016 critical appraisal in Biologics Targets and Therapy reviewed siltuximab, an interleukin 6 directed antibody, in Castleman disease and discussed the evidence base supporting its use in that rare lymphoproliferative disorder (PMID 26869762). The appraisal noted the small patient numbers inherent to rare disease research, which limits how far conclusions generalise (PMID 26869762).

Research Areas at a Glance

Where the Evidence Is Weak or Absent

Several uses attached to the word interleukin in general conversation are not supported by the literature cited here. There is no study in this citation set examining interleukin for fat loss, muscle growth, skin rejuvenation, hair growth, sleep, libido or cognitive performance in healthy adults, and absence of a study is not the same as a negative result; it simply means the question has not been answered by the papers reviewed on this page. Research on interleukin 33 in childhood asthma reported an association between measured cytokine levels and disease status rather than any treatment effect (PMID 28410870), and the liver cancer literature treated interleukins largely as biomarkers and biology rather than as general wellness interventions (PMID 32142718). Interleukin research is also not a single body of evidence that can be summarised as one answer, since blocking interleukin 17 in skin disease (PMID 39982633) and administering interleukin 12 in tumours (PMID 33004432) are opposite interventions.

Adverse Events: What Studies Report

Toxicity is a recurring theme across the interleukin literature. The 2024 interleukin 2 review reported that systemic toxicity has limited high dose interleukin 2 strategies in oncology and shaped interest in lower dose approaches aimed at regulatory T cells (PMID 38421721). The 2020 interleukin 12 commentary described systemic toxicity as a central reason that delivery engineering became the focus of the field (PMID 33004432). On the blocking side, the 2019 European Heart Journal review of cardiovascular immunotherapy discussed infection risk as the principal trade off when inflammatory signalling is suppressed (PMID 31121017), a concern echoed in the discussion of interleukin 1 beta targeted strategies in atherosclerosis (PMID 31078457). The sepsis reanalysis is a reminder that an intervention can appear neutral in a whole trial population while a defined subgroup behaves differently (PMID 26584195).

How to Read This Literature

• Name the interleukin. Findings for interleukin 5 in eosinophilic vasculitis (PMID 40305320) say nothing about interleukin 2 in cancer (PMID 38421721).
• Name the direction. Supplying a cytokine and neutralising it have opposite intents, as the psoriasis pipeline review illustrates for interleukin 17 blockade (PMID 39982633).
• Check the evidence grade. A pooled meta analysis (PMID 28410870) carries different weight than a review combining published data with expert opinion (PMID 30521057).
• Check the population. A rare disease appraisal involves small numbers by definition (PMID 26869762).
• Separate mechanism from outcome. Signalling work on interleukin 2 and STAT5 explains biology without establishing a clinical result (PMID 24058794).

Closing Summary

Across the papers summarised here, interleukin research has concentrated on oncology (PMID 38421721), inflammatory skin disease (PMID 39982633), eosinophil driven disease (PMID 40305320), cardiovascular inflammation (PMID 31078457) and defined critical care subgroups (PMID 26584195). This page is not guidance. This page is for educational purposes only and is not medical advice; consult a licensed physician about any individual health question.

References

• Next-Generation Anti-IL-17 Agents for Psoriatic Disease: A Pipeline Review (American Journal of Clinical Dermatology, 2025)
• Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies (Biomolecules, 2025)
• An Updated Review of Interleukin-2 Therapy in Cancer and Autoimmune Diseases (Journal of Interferon and Cytokine Research, 2024)
• Potential Therapeutic Value of Interleukin 1b-targeted Strategies in Atherosclerotic Cardiovascular Disease (Revista Espanola de Cardiologia, 2019)
• Systematic review of the roles of interleukins in hepatocellular carcinoma (Clinica Chimica Acta, 2020)
• Interleukin-33 in children with asthma: A systematic review and meta-analysis (Allergologia et Immunopathologia, 2017)
• Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial (Critical Care Medicine, 2016)
• Interleukin-2 and STAT5 in regulatory T cell development and function (JAK-STAT, 2013)
• Immunotherapy for cardiovascular disease (European Heart Journal, 2019)
• Interleukin-12 Message in a Bottle (Clinical Cancer Research, 2020)
• Emerging treatments in Castleman disease: a critical appraisal of siltuximab (Biologics Targets and Therapy, 2016)
• Nail Psoriasis: An Updated Review and Expert Opinion on Available Treatments, Including Biologics (Acta Dermato-Venereologica, 2019)